[Federal Register Volume 63, Number 210 (Friday, October 30, 1998)] [Notices] [Pages 58404-58405] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 98-29072] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, Public Health Service, DHHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. [[Page 58405]] Cannabinoids As Neuroprotectants A Hampson, J Axelrod, M Grimaldi (NIMH) DHHS Reference Nos. E-287-97/0 filed 21 Apr 98 and E-287-97/1 filed 10 Aug 98 Licensing Contact: Stephen Finley, 301/496-7735 ext. 215 This technology describes the neuroprotective properties of cannabidiol (CBD), 2-[3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1y1]-5- pentyl-1,3-benzenediol. Cannabidiol is a neuroprotective cannabinoid that does not possess the psychoactive qualities which have previously hampered the development of cannabinoid-based therapeutics. Cannabidiol is an effective blood-brain barrier permeable antioxidant, that is more potent than either tocopherol or ascorbate. As reported in PNAS 95, 8268-73 (July 1998), CBD can protect neurons from both glutamate and free radical induced toxicity. It is believed that CBD may present a viable alternative for treatment of ischemia or physical traumas. This technology is currently available for either licensing or collaborative efforts under a Cooperative Research and Development Agreement (CRADA). Methods and Compositions for Inhibiting Inflammation and Angiogenesis K Kelly (NCI) PCT/US97/19772 filed 24 Oct 97 (claiming priority of USSN 60/027,871 filed 25 Oct 96) Licensing Contact: Charles Maynard, 301/496-7735 ext. 243 The invention provides compositions and methods directed to isolatedsubunits of the 7TM protein CD97. CD97 is a heterodimer existing in three isoforms, namely three forms of subunit and one invariant subunit. The invention provides compositions and methods for detecting a subunit of CD97, a T-cell protein which is upregulated in activated T-cells and is involved in the onset and maintenance of inflammation and angiogenesis. The invention provides an isolated protein comprising a soluble CD97 subunit, and an isolated nucleic acid encoding a soluble CD97 subunit protein. The invention also provides methods for identifying compounds which inhibit soluble CD97 subunit expression. The invention may be used to inhibit angiogenesis associated with chronic inflammation in a mammal by administering a therapeutically effective amount of a CD97 antagonist. Another application includes determining the degree of inflammation at a site in a mammal with an antibody composition specifically reactive to a soluble CD97 subunit. Further, it should be noted that these compositions and methods have in vitro utility in the construction of proteins and subsequences thereof for the construction of antibodies, and nucleic acids and subsequences thereof for use as probes. Genetic Polymorphisms Of Interleukin-1 Alpha And Beta Associated With Early Onset Periodontitis SR Diehl, HA Schenkein, YF Wang (NIDR) Serial No. 09/035,220 filed 05 Mar 97 Licensing Contact: Dennis Penn, 301/496-7056 ext. 211 Periodontal disease occurs in 10-20% of adults, and constitutes a major cause of tooth loss. About 0.5% of U.S. adolescents between the ages of 14 to 17 years old (about 70,000) have localized early onset periodontitis and 0.1% (17,000) have the more destructive form known as generalized early onset periodontitis. Both types of early onset periodontitis often lead to tooth loss before the age of 20. Extrapolation of these figures up to age 35 leads to estimates of early onset periodontitis having a major impact on the dental health of 400,000 individuals in the U.S. population. Discovery of genetic polymorphisms at the interleukin 1 alpha and 1 beta genes significantly associated with disease risk allows genetic testing to be used to predict disease prior to onset. This can be used to target clinical efforts for disease prevention to those individuals at greatest risk. The genetic test can also justify more aggressive therapeutic treatments for individuals already affected by the early onset periodontitis who, based on their genetic profile, are predicted to exhibit very rapid disease progression. Dated: October 24, 1998. Jack Spiegel, Director, Division of Technology Development and Transfer, Office of Technology Transfer. [FR Doc. 98-29072 Filed 10-29-98; 8:45 am] BILLING CODE 4140-01-M